If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How quickly is Kisunla™ (donanemab-azbt) eliminated from the body?
The elimination half-life of Kisunla (donanemab) is approximately 12.1 days.
See important safety information, including boxed warning, in the attached prescribing information.
Additional Pharmacokinetic Characteristics
Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.1
Donanemab has a
- half-life of approximately 12.1 days, and
- clearance of 0.0255 L/h.1
Accumulation of less than 1.3 fold occurs with every-4-week dosing.1
Enclosed Prescribing Information
Reference
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 07, 2023